Impacts of sarcopenia on prostate cancer patients undergoing docetaxel chemotherapy

被引：0
|
作者：
Lin, Jacky [1 ]
Tyler, Gemma [1 ]
Linker, Joshua [1 ]
Shen, Dennis [1 ]
Zwan, Benjamin [2 ]
Ho, Nathan [1 ]
Chan, Matthew [3 ,4 ]
Arasaratnam, Malmaruha [3 ,4 ]
机构：
[1] Univ New England, Armidale, NSW, Australia
[2] Gosford Hosp, Dept Radiat Oncol, Gosford, NSW, Australia
[3] Gosford Hosp, Dept Med Oncol, Gosford, NSW, Australia
[4] Wyong Hosp, Gosford, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [1] Hypersensitivity Reactions in Men with Prostate Cancer Undergoing Docetaxel Chemotherapy
    Garadi, K.
    Ling, O.
    Saeed, F.
    Pezaro, C.
    CLINICAL ONCOLOGY, 2022, 34 (03) : E145 - E145
  • [2] Prognostic Impact of Sarcopenia in Patients With Biliary Tract Cancer Undergoing Chemotherapy
    Meguro, Koki
    Hosono, Kunihiro
    Sato, Motokazu
    Sugimoto, Yuichi
    Takai, Yusuke
    Kurita, Yusuke
    Kanoshima, Kenji
    Shimizu, Tomoki
    Sakai, Eiji
    Nakajima, Atsushi
    IN VIVO, 2021, 35 (05): : 2909 - 2915
  • [3] Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
    Mountzios, Ioannis
    Bournakis, Evangelos
    Efstathiou, Eleni
    Varkaris, Andreas
    Wen, Sijin
    Chrisofos, Michael
    Deliveliotis, Charalambos
    Alamanis, Christos
    Anastasiou, Ioannis
    Constantinides, Constantine
    Karadimou, Alexandra
    Tsiatas, Marinos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Dimopoulos, Meletios A.
    UROLOGY, 2011, 77 (03) : 682 - 687
  • [4] Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer
    Mangir, N.
    Turkeri, L.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (08): : 515 - 522
  • [5] Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
    Cheung, F. Y.
    Leung, K. C.
    Ngan, Roger K. C.
    HONG KONG MEDICAL JOURNAL, 2013, 19 (03) : 237 - 241
  • [6] Chemotherapy for advanced prostate cancer: Docetaxel and beyond
    Dreicer, Robert
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (04) : 935 - +
  • [7] Prostate specific antigen doubling time (PSADT) in patients with hormone refractory prostate cancer (HRPC) undergoing docetaxel chemotherapy as a predictor of overall survival
    Pachynski, R. K.
    King, C.
    Srinivas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Impacts of sarcopenia on adverse events and prognosis in Chinese patients with esophageal cancer undergoing chemoradiotherapy
    Qu, Jiaoyue
    Liu, Yang
    Yuan, Yin
    Yu, Zhao
    Ding, Jianming
    He, Zelai
    Wang, Gengming
    FRONTIERS IN NUTRITION, 2025, 12
  • [9] The effect of sarcopenia on acute chemotherapy toxicity in gastrointestinal cancer patients undergoing systemic therapy
    Ozdemir, N.
    Yazici, O.
    Silay, K.
    Ucar, G.
    Eren, T.
    Dede, D. Sener
    Sendur, M. A. N.
    Akinci, M. B.
    Baykal, A.
    Yalcin, B.
    Zengin, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Chemotherapy with docetaxel in prostate cancer. A case report
    Lechevallier, E.
    Culine, S.
    El Fegoun, A. Benchikh
    PROGRES EN UROLOGIE, 2010, 20 : S80 - S83
12345